Quality of life measurements in anti-emetic trials: a discussion of Professor Selby's paper.

Por Schmoll, H. J.
Publicado em 1992

Endocrinological late effects after chemotherapy for testicular cancer.

Por Berger, C. C., Bokemeyer, C., Schuppert, F., Schmoll, H. J.
Publicado em 1996

The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.

Por Bokemeyer, C., Schmoll, H. J., Ludwig, E., Harstrick, A., Dunn, T., Casper, J.
Publicado em 1994

Long-term effects on sexual function and fertility after treatment of testicular cancer

Por Hartmann, J T, Albrecht, C, Schmoll, H-J, Kuczyk, M A, Kollmannsberger, C, Bokemeyer, C
Publicado em 1999

MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial

Por Gormly, KLM, Coscia, C, Wells, T, Tebbutt, N, Harvey, JA, Wilson, K, Schmoll, H-J, Price, T
Publicado no Cancer Imaging (2015)

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.

Por Bokemeyer, C., Fels, L. M., Dunn, T., Voigt, W., Gaedeke, J., Schmoll, H. J., Stolte, H., Lentzen, H.
Publicado em 1996

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.

Por Bokemeyer, C., Berger, C. C., Hartmann, J. T., Kollmannsberger, C., Schmoll, H. J., Kuczyk, M. A., Kanz, L.
Publicado em 1998

Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial

Por Arnold, D, Voigt, W, Kiewe, P, Behrmann, C, Lindemann, S, Reif, S, Wiesinger, H, Giurescu, M, Thiel, E, Schmoll, H-J
Publicado em 2009

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

Por Jürgensmeier, J M, Schmoll, H-J, Robertson, J D, Brooks, L, Taboada, M, Morgan, S R, Wilson, D, Hoff, P M
Publicado em 2013

First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial

Por Bokemeyer, C, Schleucher, N, Metzner, B, Thomas, M, Rick, O, Schmoll, H-J, Kollmannsberger, C, Boehlke, I, Kanz, L, Hartmann, J T
Publicado em 2003

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial

Por Chu, E, Haller, D, Cartwright, T, Twelves, C, Cassidy, J, Sun, W, Saif, M W, McKenna, E, Lee, S, Schmoll, H-J
Publicado em 2014

Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials

Por Bokemeyer, C, Kollmannsberger, C, Stenning, S, Hartmann, J T, Horwich, A, Clemm, C, Gerl, A, Meisner, C, Rückerl, C-P, Schmoll, H-J, Kanz, L, Oliver, T
Publicado em 2004

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis ge...

Por Daugaard, G., Skoneczna, I., Aass, N., De Wit, R., De Santis, M., Dumez, H., Marreaud, S., Collette, L., Lluch, J. R. G., Bokemeyer, C., Schmoll, H. J.
Publicado em 2011

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trial...

Por Haller, D. G., O'Connell, M. J., Cartwright, T. H., Twelves, C. J., McKenna, E. F., Sun, W., Saif, M. W., Lee, S., Yothers, G., Schmoll, H.-J.
Publicado no Ann Oncol (2015)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorect...

Por Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., Giessen-Jung, C., Stahler, A., Schmoll, H. J., Jung, A., Kirchner, T., Tannapfel, A., Reinacher-Schick, A.
Publicado no Ann Oncol (2016)

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

Por Bleiberg, H., Decoster, G., de Gramont, A., Rougier, P., Sobrero, A., Benson, A., Chibaudel, B., Douillard, J. Y., Eng, C., Fuchs, C., Fujii, M., Labianca, R., Larsen, A. K., Mitchell, E., Schmoll, H. J., Sprumont, D., Zalcberg, J.
Publicado no Ann Oncol (2017)